Anthelmintic Drugs Market Report 2026

Anthelmintic Drugs Market Overview

• Anthelmintic Drugs market size has reached to $3.34 billion in 2025 • Expected to grow to $4.32 billion in 2030 at a compound annual growth rate (CAGR) of 5.2% • Growth Driver: Increasing Parasitic Infections To Drive Market Growth For Anthelmintic Drugs • Market Trend: Advancing Parasite Control With Targeted Deworming • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Anthelmintic Drugs Market?

Anthelmintic drugs are medications used to treat infections caused by parasitic worms, or helminths. These drugs work by either killing the worms directly or disrupting their ability to reproduce. They are commonly prescribed for conditions such as roundworm, tapeworm, and hookworm infections. The main drug classes of anthelmintic drugs are benzimidazoles, macrocyclic lactones, pyrazinoisoquinolones, tetrahydropyrimidines, and others. Benzimidazoles are a class of organic compounds characterized by a benzene ring fused with an imidazole ring. They are used in various applications, including as pharmaceutical agents for treating parasitic infections and as key components in some synthetic materials. They are administered via oral and injectable routes to treat various infections, including nematode, cestode, trematode, and mixed infections. They are distributed through various channels such as hospitals and clinics, retail pharmacies, online pharmacies, and veterinary clinics and supply stores, and are applied in human and veterinary anthelmintics.

What Is The Anthelmintic Drugs Market Growth Forecast?

The anthelmintic drugs market size is expected to see strong growth in the next few years. It will grow to $4.32 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to development of novel anthelmintic compounds, increasing adoption of combination therapies, rising veterinary and livestock applications, expansion of online and retail pharmacy channels, government initiatives for parasite control programs. Major trends in the forecast period include rising prevalence of helminth infections in humans and animals, growing adoption of oral anthelmintics and injectable formulations, increasing demand for veterinary anthelmintics in livestock management, expansion of retail and online pharmacy channels for anthelmintic drugs, focus on combination therapies and broad-spectrum anthelmintics.

Global Anthelmintic Drugs Market Segmentation

1) By Drug Class: Benzimidazoles, Macrocyclic lactones, Pyrazinoisoquinolones, Tetrahydropyrimidines, Other Drug Classes 2) By Route Of Administration: Oral, Injectable 3) By Infection Type: Nematode Infections, Cestode Infections, Trematode Infections, Mixed Infections 4) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies, Online Pharmacies, Veterinary Clinics And Supply Stores 5) By Application: Human Anthelmintics, Veterinary Anthelmintics Subsegments: 1) By Benzimidazoles: Albendazole, Mebendazole, Fenbendazole, Oxfendazole, Thiabendazole 2) By Macrocyclic Lactones: Ivermectin, Moxidectin, Doramectin, Eprinomectin, Milbemycin Oxime 3) By Pyrazinoisoquinolones: Praziquantel, Cysticide 4) By Tetrahydropyrimidines: Pyrantel Pamoate, Pyrantel Tartrate 5) By Other Drug Classes: Imidazothiazoles, Aminoacetonitrile Derivatives, Spiroindoles, Arsenicals

What Is The Driver Of The Anthelmintic Drugs Market?

The high prevalence of parasitic infections is expected to propel the growth of the anthelmintic drugs market going forward. Parasitic infections are diseases caused by organisms that live on or inside another host, such as parasites such as protozoa, worms, or ectoparasites. Parasitic infections are fueled by poor sanitation, contaminated food or water, close contact with infected individuals or animals, inadequate hygiene, and a lack of access to clean resources. Anthelmintic drugs are used to treat infections caused by parasitic worms, effectively targeting and eliminating these parasites from the host's body. These medications work by disrupting the parasites' physiological functions, leading to their expulsion or death. For instance, in September 2025, according to the data published by the Centers for Disease Control and Prevention, a US-based national public health agency, as of September 16, 2025, the CDC had received reports of 990 cases of cyclosporiasis acquired in the United States. Therefore, the high prevalence of parasitic infections is driving the growth of the anthelmintic drugs industry.

Key Players In The Global Anthelmintic Drugs Market

Major companies operating in the anthelmintic drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Zoetis Inc., Hetero Labs Limited, Sun Pharmaceutical Industries Ltd., Galderma S.A., Cipla Inc., Ferring Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Mankind Pharma Ltd., Reese Pharmaceutical Company

Global Anthelmintic Drugs Market Trends and Insights

Major companies operating in the anthelmintic drugs market are focusing on developing innovative solutions, such as targeted, evidence-based deworming programs, to improve parasite control, reduce drug resistance, and promote sustainable use of anthelmintics compared with traditional blanket deworming approaches that often rely on frequent, untargeted treatments. Targeted deworming programs leverage diagnostic testing, parasite load assessment, and strategic dosing schedules to optimize treatment efficacy while minimizing environmental and resistance risks. For instance, in April 2025, Zoetis Inc., a US-based animal health company, launched the “Buy Less Dewormer” campaign for equine populations, promoting evidence-based parasite management. The program combines educational resources with guidance on fecal egg count monitoring and strategic anthelmintic selection; it functions by encouraging horse owners and veterinarians to administer treatments only when necessary, based on parasite burden and risk assessment; unique features include integrated educational materials, risk-based treatment recommendations, and support for sustainable anthelmintic stewardship; applications span equine herd health management, prevention of parasite resistance, and optimized deworming schedules; benefits include reduced anthelmintic overuse, improved parasite control outcomes, lower costs for owners, and promotion of long-term drug efficacy.

What Are Latest Mergers And Acquisitions In The Anthelmintic Drugs Market?

In July 2023, Bayer AG, a Germany-based pharmaceutical and biotechnology company, partnered with the Swiss Tropical and Public Health Institute (Swiss TPH) to develop anthelmintic drug compounds for treating parasitic infections. The collaboration aims to evaluate the safety and efficacy of emodepside, a compound initially developed for veterinary use, for human treatment of soil-transmitted helminths, provide a new treatment option and advance global health efforts by addressing a major public health challenge in developing regions. The Swiss Tropical and Public Health Institute (Swiss TPH) is a Switzerland-based research institute that focuses on global health and tropical diseases.

Regional Insights

North America was the largest region in the anthelmintic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Anthelmintic Drugs Market?

The anthelmintic drugs market consists of sales of albendazole, mebendazole, praziquantel, levamisole, piperazine, and ivermectin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Anthelmintic Drugs Market Report 2026?

The anthelmintic drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the anthelmintic drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.